Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Change in Account Payables of -$575000.0 for Q2 2026, up 48.34% year-over-year from -$387628.7 in Q2 2025, and down 177.18% quarter-over-quarter from $745000.0 in Q1 2026.
Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Change in Account Payables for 17 consecutive years, with -$575000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables rose 48.34% year-over-year to -$575000.0; the TTM figure through Jun 2026 stood at $1.3 million (up 131.01% YoY), while the FY2025 annual figure was $42000.0, up 101.68% from the prior year.
- Change in Account Payables declined to -$575000.0 in Q2 2026 per ANIK's latest filing, from $745000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.4 million in Q4 2022 and bottomed at -$2.9 million in Q3 2024.
- Historically, Change in Account Payables has averaged -$18888.9 across 5 years, with a median of $97500.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Account Payables slumped 911.72% — and 2026, when it surged 1485.11%.
- Anika Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then slipped by 8.66% to $1.3 million in 2023, then plunged by 109.25% to -$121000.0 in 2024, then jumped by 824.79% to $877000.0 in 2025, then tumbled by 165.56% to -$575000.0 in 2026.
- Business Quant data shows ANIK's Change in Account Payables at -$575000.0 in Q2 2026, $745000.0 in Q1 2026, and $877000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | -575,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -575,000.00 |
| Jun 30, 2026 | -575,000.00 |
| Mar 31, 2026 | 745,000.00 |
| Mar 31, 2026 | 745,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.11 Mn |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Sep 30, 2024 | -2.93 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | 148,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Mar 31, 2024 | 401,000.00 |